BMS 823778

Drug Profile

BMS 823778

Alternative Names: BMS823778

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antihyperglycaemics; Antihyperlipidaemics
  • Mechanism of Action 11-beta hydroxysteroid dehydrogenase type 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hypercholesterolaemia; Type 2 diabetes mellitus

Most Recent Events

  • 23 Aug 2013 Bristol-Myers Squibb terminates a phase II trial for Hypertension (in overweight and obese patients) early in recruitment in the US, the EU and Latin America (NCT01602367)
  • 15 Jul 2013 Bristol-Myers Squibb withdraws a phase II trial for Artherosclerosis prior to enrolment (NCT01666704)
  • 28 Aug 2012 Bristol-Myers Squibb plans a phase II trial for Artherosclerosis in USA (NCT01666704)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top